Michael Pietila, MD
Pulmonary Disease · Yankton, SDNPI 1740254986
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,173 of the $79,241 with a category attached, or 69.6%. Mylan Specialty L.p. accounts for 86.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $22,660 and has fallen 55.7% since, to $10,030 in 2025. Among pulmonary disease clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 233 payments — averaging $340.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$68K
- Viatris Specialty LLC$9K
- AstraZeneca$757
- Regeneron Healthcare Solutions, Inc.$371
- Boehringer Ingelheim$186
- Phathom Pharmaceuticals, Inc.$84
- plus $435 from 14 others
What the payments were for
- Consulting fees$16,66521%
- Speaking & faculty fees$55,17370%
- Travel & lodging$4,1205%
- Food & beverage$3,2204%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 143 | $68,163 |
| Viatris Specialty LLC | 28 | $9,244 |
| AstraZeneca | 24 | $757 |
| Regeneron Healthcare Solutions, Inc. | 16 | $371 |
| Boehringer Ingelheim | 2 | $186 |
| Phathom Pharmaceuticals, Inc. | 1 | $84 |
| Actelion Pharmaceuticals US, Inc. | 1 | $59 |
| Insmed, Inc. | 3 | $52 |
| Amgen | 3 | $52 |
| Boston Scientific | 1 | $49 |
| Baxter Healthcare | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 1 | $28 |
| Advanced Respiratory, Inc | 1 | $22 |
| Resmed Corp | 1 | $22 |
| Philips North America LLC | 1 | $21 |
| Sanofi | 1 | $18 |
| GSK | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,241 in reported general payments places this provider in the 95th percentile of 35 pulmonary disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 372 | $288,995 |
| Breo ElliptaFluticasone/Vilanterol | 110 | $60,229 |
| Spiriva RespimatTiotropium Bromide | 95 | $52,342 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 95 | $50,659 |
| Dupixent SyringeDupilumab | 13 | $43,726 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 73 | $41,373 |
| EliquisApixaban | 42 | $34,024 |
| Spiriva HandihalerTiotropium Bromide | 43 | $22,476 |
| Arnuity ElliptaFluticasone Furoate | 76 | $18,221 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $16,863 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $13,910 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $10,902 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $10,247 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 175 | $5,584 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $5,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $18 | $434,968698 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $186 | $104,617190 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $757 | $15,10829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 pulmonary disease providers in South Dakota.
Other pulmonary disease in Yankton
- Scott HelbergYankton$621K
- Lori HansenYankton$10K
- Svien SenneWatertown$13K
- Joevasanth DevasahayamSioux Falls$8K
- Matthew TaylorSioux Falls$8K
- Cliff JanikowskiRapid City$6K
- Fady JamousSioux Falls$6K
- Rizan HajalSioux Falls$5K
- Deptmer AshleyAberdeen$5K
- Kaitlin BranickSioux Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.